DOI: 10.36347/sjmcr.2017.v05i09.015

Pages: 560-561

Anticoagulant agents are primary choice for avoiding and treatment of systemic thromboembolism in patients with atrial fibrillation (AF). Currently, a huge progression in the management of clinical thromboembolism has been made owing to the innovation of new oral anticoagulants (NOACs). They have various useful benefits over the conventional vitamin K antagonists, such as not necessary for classic coagulation follow-up. Although there is a restricted drug and food interaction with NOACs; sometimes, especially using some antibiotics, we can observe some drug reactions in clinical practice.